GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Suzhou Basecare Medical Corp Ltd (HKSE:02170) » Definitions » 3-Year FCF Growth Rate

Suzhou Basecare Medical (HKSE:02170) 3-Year FCF Growth Rate : -66.50% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Suzhou Basecare Medical 3-Year FCF Growth Rate?

Suzhou Basecare Medical's Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$-0.79.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -66.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -74.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Suzhou Basecare Medical was -66.50% per year. The lowest was -101.20% per year. And the median was -97.20% per year.


Competitive Comparison of Suzhou Basecare Medical's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Suzhou Basecare Medical's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Basecare Medical's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Suzhou Basecare Medical's 3-Year FCF Growth Rate falls into.



Suzhou Basecare Medical 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Suzhou Basecare Medical  (HKSE:02170) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Suzhou Basecare Medical 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Suzhou Basecare Medical's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Basecare Medical (HKSE:02170) Business Description

Traded in Other Exchanges
N/A
Address
BioBay, No. 218 Xinghu Street, Unit 101, Building A3, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Suzhou Basecare Medical Corp Ltd is engaged in providing genetic testing solutions for assisted human reproduction. The company generates revenues from Sales of testing kits, followed by Sales of testing devices and instruments. Basecare focuses on the assisted reproductive sector, such as pre-implantation genetic screening and diagnosis, non-invasive prenatal DNA testing, and chromosome abnormalities testing. It generates revenue from China.
Executives
Orbimed Capital Llc 2102 Investment manager
Lake Bleu Prime Healthcare Master Fund Limited 2201 Interest of corporation controlled by you
Orbimed Partners Master Fund Limited 2101 Beneficial owner
Dawn Capital Fund 2101 Beneficial owner
Dawn Capital Limited 2102 Investment manager
Hh Spr-xiv Cy Holdings Limited 2201 Interest of corporation controlled by you
Hh Spr-xiv Hk Holdings Limited 2101 Beneficial owner
Hh Spr-xiv Holdings L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager

Suzhou Basecare Medical (HKSE:02170) Headlines

No Headlines